Clinical Trials Browser

Phase 1/2 × mirdametinib × 90 days × Clear all

NCT06876142 2026-03-19

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06843967 2026-03-13

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Phase 1/2 Recruiting

Liposarcoma, Liposarcoma, Myxoid